SI1944026T1 - Use of EDG receptor binding agents in cancer - Google Patents

Use of EDG receptor binding agents in cancer

Info

Publication number
SI1944026T1
SI1944026T1 SI200332293T SI200332293T SI1944026T1 SI 1944026 T1 SI1944026 T1 SI 1944026T1 SI 200332293 T SI200332293 T SI 200332293T SI 200332293 T SI200332293 T SI 200332293T SI 1944026 T1 SI1944026 T1 SI 1944026T1
Authority
SI
Slovenia
Prior art keywords
cancer
receptor binding
binding agents
edg receptor
edg
Prior art date
Application number
SI200332293T
Other languages
Slovenian (sl)
Inventor
Thomas Baumruker
Volker Brinkmann
Montagne Kenneth Richard La
Peter T Lassota
Diana Mechtcheriakova
Jeanette Marjorie Wood
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0211261A external-priority patent/GB0211261D0/en
Priority claimed from GB0217150A external-priority patent/GB0217150D0/en
Application filed by Novartis Ag, Novartis Pharma Gmbh filed Critical Novartis Ag
Priority claimed from EP08152489.4A external-priority patent/EP1944026B1/en
Publication of SI1944026T1 publication Critical patent/SI1944026T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
SI200332293T 2002-05-16 2003-05-15 Use of EDG receptor binding agents in cancer SI1944026T1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0211261A GB0211261D0 (en) 2002-05-16 2002-05-16 Organic compounds
US39041102P 2002-06-20 2002-06-20
GB0217150A GB0217150D0 (en) 2002-07-24 2002-07-24 Organic compounds
US44973903P 2003-02-24 2003-02-24
EP08152489.4A EP1944026B1 (en) 2002-05-16 2003-05-15 Use of EDG receptor binding agents in cancer

Publications (1)

Publication Number Publication Date
SI1944026T1 true SI1944026T1 (en) 2013-10-30

Family

ID=43508462

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200332293T SI1944026T1 (en) 2002-05-16 2003-05-15 Use of EDG receptor binding agents in cancer

Country Status (7)

Country Link
KR (5) KR101299873B1 (en)
DK (1) DK1944026T3 (en)
ES (1) ES2428697T3 (en)
PL (1) PL396723A1 (en)
PT (1) PT1944026E (en)
SI (1) SI1944026T1 (en)
TW (2) TWI341197B (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1180026A (en) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd New immunosuppressant, its use and its identification

Also Published As

Publication number Publication date
KR101299873B1 (en) 2013-08-23
KR20110094154A (en) 2011-08-19
PL396723A1 (en) 2011-12-19
TW200906381A (en) 2009-02-16
KR20050003460A (en) 2005-01-10
TW200307533A (en) 2003-12-16
KR20100133027A (en) 2010-12-20
DK1944026T3 (en) 2013-09-30
TWI341197B (en) 2011-05-01
KR20130088904A (en) 2013-08-08
ES2428697T3 (en) 2013-11-08
KR20120025018A (en) 2012-03-14
TWI340036B (en) 2011-04-11
PT1944026E (en) 2013-09-18

Similar Documents

Publication Publication Date Title
EP1482895A4 (en) Aminoalkylphosphonates and related compounds as edg receptor agonists
AP1916A (en) Purine compounds and use thereof as cannabinoid receptor ligands
EP1535610A4 (en) Therapeutic agent for cancer
EP1482896A4 (en) Aminoalkylphosphonates and related compounds as edg receptor agonists
PL383616A1 (en) Agents binding and inhibiting miostatin
AU2003222604A8 (en) Proteins involved in breast cancer
PL379553A1 (en) Vanilloid receptor ligands and their use in treatments
AU2003213144A1 (en) Alkylating agent combinations in the treatment of cancer
IL166396A0 (en) Vanilloid receptor ligands and their use in treatments
AU2003235470A8 (en) Predictive markers in cancer therapy
EP1482970A4 (en) Cancer therapy
HUP0401903A3 (en) Improved use of et-743 in cancer thereapy
HUP0300005A3 (en) Modified cytokines for use in cancer therapy
TWI340641B (en) N-acylamino benzyl ether derivatives
IL173265A0 (en) Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazcpine receptor ligands
AU2003255544A8 (en) Tumor specific oligosaccharide epitopes and use thereof
GB0204800D0 (en) Dispensing wallets
IL161762A0 (en) Estradiol inhibiting agents in breast cancer
HRP20041037A2 (en) Binding agents and their use in targeting tumor cells
TWI341197B (en) Use of edg receptor binding agents in cancer
GB0226595D0 (en) Cancer therapy determination
EP1587405A4 (en) Novel compositions and methods for cancer
AU2003221886A8 (en) Beta2-microglobilin (beta2m) and anti-beta2m binding agents as anti-cancer therapeutics
EP1701736A4 (en) Therapeutic agents and uses therefor
GB0305348D0 (en) Membrane-associated protein in cancer